Paper

1. Masaki Gomi, Yu Sakurai, Minami Sato, Hiroki Tanaka, Yumi Miyatake, Koichi Fujiwara, Mizuki Watanabe, Satoshi Shuto, Yuta Nakai, Kota Tange, Hiroto Hatakeyama, Hidetaka Akita. Delivering mRNA to Secondary Lymphoid Tissues by Phosphatidylserine-loaded Lipid Nanoparticles. Adv Healthc Mater, 12(9) e 2202528 (2023) (IF 11.092)    https://pubmed.ncbi.nlm.nih.gov/36535635/
2. Mizuki Doi, Hiroki Tanaka, Takara Ohoto, Naoya Miura, Yu Sakurai, Hiroto Hatakeyama, Hidetaka Akita. Reactivation of anti-cancer immunity by resetting inter-organ crosstalk in immune-suppressive cells with a nano-particulated anti-inflammatory drug. Small, 2205131 (2023) (IF 15.153)       https://onlinelibrary.wiley.com/doi/full/10.1002/smll.202205131
3. Hiroki Hanaka, Shinya Hagiwara, Daiki Shirane, Takuma Yamakawa, Yuka Sato, Chika Matsumoto, Kota Ishizaki, Miho Hishinuma, Katsuyuki Chida, Kasumi Sasaki, Etsuo Yonemochi, Keisuke Ueda, Kenjiro Higashi, Kunikazu Moribe, Tkashi Tadokoro,  Kastumi Maenaka, Sakura Taneichi, Yuta Nakai, Kota Tange, Yu Sakurai, Hidetaka Akita. Ready-to-Use-type lyophilized lipid nanoparticle formulation for the post-encapsulation of messenger RNA. ACS Nano 17, 2588-2601 (2023) (IF 15.881)   https://pubs.acs.org/doi/10.1021/acsnano.2c10501
4. Yuta Tamemoto a, Yukihiro Shibata a b, Natsumi Hashimoto a, Hiromi Sato a, Akihiro Hisaka. Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants. Drug Metab Pharmacokinet, 53, 100498 (2023) (IF=2.1) doi: 10.1016/j.dmpk.2023.100498.
5. Jessica Anindita, Hiroki Tanaka, Ryotaro Oyama, Shinya Hagiwara, Daiki Shirane, Sakura Taneichi, Yuta Nakai, Kota Tange, Hiroto Hatakeyama, Yu Sakurai, Hidetaka Akita. Development of a Ready-to-Use-type RNA vaccine carrier based on an intracellular environment-responsive lipid-like material with immune-activating vitamin E-scaffolds. Pharmaceutics, 15(12), 2702 (2023) (IF=5.4)

Invited lecture

1. Hiroto Hatakeyama. Elucidation of pharmacokinetic factors affecting the efficacy of immune checkpoint inhibitors. JSP/CSPS Joint Symposium, the 143rd Annual Meeting of the Pharmaceutical Society of Japan. March, 25, 2023. Sapporo.
2. Hiroto Hatakeyama. Elucidation of pharmacokinetic factors affecting the efficacy of immune checkpoint inhibitors. Faculty of Pharmacy and Pharmaceutical Sciences Seminar Series, the University of Alberta. May 23, 2023. Edmonton, Alberta, Canada
3. Hiroto Hatakeyama. Elucidation of pharmacokinetic factors affecting the efficacy of immune checkpoint inhibitors. Canadian Society of Pharmaceutical Sciences Annual Symposium. May 26, 2023. Toronto, Ontario, Canada.
4. Hiroto Hatakeyama. Re-thinking of delivery strategy of biologics and nano DDSto tumor: beyond the EPR effect. 2023 ICCP/JSSX International Joint Meeting. September 26, 2023. Shizuoka
5. Hiroto Hatakeyama. Exploring of pharmacokinetic factors affecting the efficacy and adverse events of immune checkpoint inhibitors. 2023 ICCP/JSSX International Joint Meeting. September 28, 2023. Shizuoka (Young Investigator Award lecture)

Conference (International)

1. Ryota Tsuda, Mayu Yamamoto, Yui Matsumoto, Chongjie Zhang, Yuta Tamemoto, Hiroto Hatakeyama. 2023 ICCP/JSSX International Joint Meeting. September 27, 2023. Shizuoka (Poster)
2. Hana Kumemura, Yuta Tamemoto, Shizuka Hozuki, Hiromi Sato, Akihiro Hisaka. A new approach to evaluate in vivo inhibition ratio of CYP3A based on data from adverse event reporting system without using pharmacokinetic information. 2023 ICCP/JSSX International Joint Meeting. September 27, 2023. Shizuoka (Poster)
3. Natsumi Hashimoto, Yuta Tamemoto, Keita Takahashi, Hana Kumemura, Hiromi Sato, Akihiro Hisaka. Significance of choice of substrate drugs and buffer conditions which affect the assessment of in vitro inhibition of metabolism by CYP3A. 2023 ICCP/JSSX International Joint Meeting. September 27, 2023. Shizuoka (Poster)